Bronchodilation of umeclidinium, a new long-acting muscarinic antagonist, in COPD patients

Respiratory Physiology and Neurobiology

Volumn 185, Issue 2, 2013, Pages 393-399

  Decramer, Marc ^a   Maltais, François ^b   Feldman, Gregory ^c   Brooks, Jean ^d   Harris, Stephanie ^e   Mehta, Rashmi ^e   Crater, Glenn ^e  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b LAVAL UNIVERSITY   (Canada)

^c Research South Carolina Pharmaceutical Research   (United States)

^d GLAXOSMITHKLINE   (United Kingdom)

^e GLAXOSMITHKLINE   (United States)

Author keywords

Anticholinergic; Chronic obstructive pulmonary disease; GSK573719; Long acting bronchodilator; Long acting muscarinic receptor antagonist; Umeclidinium

Indexed keywords

CORTICOSTEROID; GSK 73719; PLACEBO; SALBUTAMOL; UMECLIDINIUM; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BACKACHE; BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; COUGHING; CYSTITIS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DYSGEUSIA; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NOSE OBSTRUCTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; SINUS CONGESTION; SPUTUM; UPPER ABDOMINAL PAIN; VIRAL GASTROENTERITIS; XEROSTOMIA;

ADULT; AGED; AGED, 80 AND OVER; BRONCHODILATOR AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG VOLUME MEASUREMENTS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUINUCLIDINES; RETROSPECTIVE STUDIES; SPIROMETRY;

EID: 84871923164     PISSN: 15699048     EISSN: 18781519     Source Type: Journal    
DOI: 10.1016/j.resp.2012.08.022     Document Type: Article

References (26)

1. Bardsley P.A. Chronic respiratory failure in COPD: is there a place for a respiratory stimulant?. Thorax 1993, 48:781-784.
2. Casaburi R., Mahler D.A., Jones P.W., Wanner A., San P.G., ZuWallack R.L., Menjoge S.S., Serby C.W., Witek T. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. European Respiratory Journal 2002, 19:217-224.
3. Casaburi R., Briggs D.D., Donohue J.F., Serby C.W., Menjoge S.S., Witek T.J. The spirometric efficacy of once-daily dosing with tiotropium in stable COPD: a 13-week multicenter trial. The US Tiotropium Study Group. Chest 2000, 118:1294-1302.
4. Celli B.R., Macnee W. Standards of the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. European Respiratory Journal 2004, 23:932-946.
5. Cerveri I., Pellegrino R., Dore R., Corsico A., Fulgoni P., van de Woestijne K.P., Brusasco V. Mechanisms for isolated volume response to a bronchodilator in patients with COPD. Journal of Applied Physiology 2000, 88:1989-1995.
6. Chanez P., Burge P.S., Dahl R., Creemers J., Chuchalin A., Lamarca R., Garcia Gil E. Aclidinium bromide provides long-acting bronchodilation in patients with COPD. Pulmonary Pharmacology and Therapeutics 2010, 23:15-21.
7. Donohue J.F., Anzueto A., Brooks J., Mehta R., Kalberg C., Crater G. A randomized, double-blind dose-ranging study of the novel LAMA GSK573719 in patients with COPD. Respiratory Medicine 2012, 106:970-979.
8. Dusser D., Bravo M.L., Iacono P. The effect of tiotropium on exacerbations and airflow in patients with COPD. European Respiratory Journal 2006, 27:547-555.
9. Global Initiative for Chronic Obstructive Lung Disease (GOLD) Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease 2011 December, (accessed February 2012). http://www.goldcopd.com/.
10. Hanania N.A., Feldman G., Zachgo W., Shim J.J., Crim C., Sanford L., Lettis S., Barnhart F., Haumann B. The efficacy and safety of the novel long-acting beta2-agonist vilanterol in COPD patients: a randomized placebo-controlled trial. Chest 2012, (Epub ahead of print).
11. Hankinson J.L., Odencrantz J.R., Freden K.B. Spirometric reference values from a sample of the general US population. American Journal of Respiratory and Critical Care Medicine 1999, 159:179-187.
12. Jones P.W., Rennard S.I., Agusti A., Chanez P., Magnussen H., Fabbri L., Donohue J.F., Bateman E.D., Gross N.J., Lamarca R., Caracta C., Gil E.G. Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease. Respiratory Research 2011, 12:55.
13. Kesten S., Jara M., Wentworth C., Lanes S. Pooled clinical trial analysis of tiotropium safety. Chest 2006, 130:1695-1703.
14. Kesten S., Celli B., Decramer M., Leimer I., Tashkin D. Tiotropium HandiHaler in the treatment of COPD: a safety review. International Journal of Chronic Obstructive Pulmonary Disease 2009, 4:397-409.
15. Laine D.I., Luttman M.A., Foley J.J., Dehass C.J., Kotzer C.J., Salmon M., Rumsey W.L. The pre-clinical pharmacology of the inhaled muscarinic antagonist GSK573719A predicts once-daily clinical dosing. European Respiratory Journal 2011, 38:723s. (abstract).
16. Lipson D.A. Tiotropium bromide. International Journal of Chronic Obstructive Pulmonary Disease 2006, 1:107-114.
17. Littner M.R., Ilowite J.S., Tashkin D.P., Friedman M., Serby C.W., Menjoge S.S., Witek T.J. Long-acting bronchodilation with once-daily dosing of tiotropium (Spiriva) in stable chronic obstructive disease. American Journal of Respiratory and Critical Care Medicine 2000, 161:1136-1142.
18. Miller M.R., Hankison J., Brusasco V., Burgos F., Casaburi R., Coates A., Crapo R., Enright P., van der Grinten C.P.M., Gustafsson P., Jensen R., Johnson D.C., MacIntyre N., McKay R., Navajas D., Perdersen O.F., Pellegrino R., Viegi G., Wanger J. Standardisation of spirometry. European Respiratory Journal 2005, 26:319-338.
19. Niewoehner D.E., Rice K., Cote C., Paulson D., Cooper J.A., Korducki L., Cassino C., Kesten S. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial. Annals of Internal Medicine 2005, 143:317-326.
20. Sims M.W., Panettieri R.A. Profile of aclidinium bromide in the treatment of chronic obstructive pulmonary disease. International Journal of Chronic Obstructive Pulmonary Disease 2011, 6:457-466.
21. Tashkin D.P., Celli B., Senn S., Burkhart D., Kesten S., Menjoge S., Decramer M. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. New England Journal of Medicine 2008, 359:1543-1554. UPLIFT Study Investigators.
22. van Noord J.A., Smeets J.J., Custers F.L., Korducki L., Cornelissen P.J. Pharmacodynamic steady state of tiotropium in patients with chronic obstructive pulmonary disease. European Respiratory Journal 2002, 19:639-644.
23. Verkindre C., Fukuchi Y., Flémale A., Takeda A., Overend T., Prasad N., Dolker M. Sustained 24-h efficacy of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients. Respiratory Medicine 2010, 104:1482-1489.
24. Vincken W., van Noord J.A., Greefhorst A.P., Bantje T.A., Kesten S., Korducki L., Cornelissen P.J. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. European Respiratory Journal 2002, 19:209-216.
25. Vogelmeier C., Banerji D. NVA237, a long-acting muscarinic antagonist, as an emerging therapy for chronic obstructive disease. Therapeutic Advances in Respiratory Disease 2011, 5:163-173.
26. Vogelmeier C. Safety and tolerability of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients. Pulmonary Pharmacology and Therapeutics 2010, 23:438-444.